+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Primary Immunodeficiency Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • ID: 4987072
  • Report
  • January 2022
  • Region: Global
  • 120 Pages
  • Mordor Intelligence


  • Baxter international Inc
  • Biotest AG
  • CSL Ltd
  • Grifols S.A
  • Kedrion Biopharma Inc
  • LFB group

The Primary Immunodeficiency Therapeutics Market is expected to register a CAGR of 6.1% during the forecast period. Primary immunodeficiencies are a group of different disorders in which part of the body's immune system (mainly cells and proteins) is missing or does not function normally. As per researchers, estimated more than 300 different kinds of primary immunodeficiency disease (PIDD). The immune system is composed of white blood cells made in the bone marrow which protect and defend against attacks by foreign invaders such as bacteria, fungi, and germs. Antibodies and Complement are proteins that are made in response to infection or immunization and helps to fight against infections and plays a protective role in the immune system. In the most common primary immunodeficiency diseases, different forms of cells or proteins are missing or do not function which results in severe infections and/or infections that are unusually hard to cure. These infections may attack the respiratory system, the brain or spinal cord, the ears, skin, or in the urinary or gastrointestinal tracts. In some instances, primary immunodeficiency diseases target specific and/or multiple organs, glands, cells, and tissues. For example, heart defects are present in some primary immunodeficiency diseases.

Treatment options for primary immunodeficiency diseases are targeted towards specific immune defects and can include transplantation bone marrow transplantation, stem cell transplantation, immunoglobulin replacement therapy, antibiotic therapy and strategies to manage primary immunodeficiency diseases. Gene therapy has been successful in specific types of primary immunodeficiency disease. Research in primary immunodeficiency disease treatment is making great strides, advance treatment options and improving the quality of life for most people with these complex conditions.

According to the National Institute of Allergy and Infectious Diseases, estimates more than 200 different forms of primary immune deficiency diseases affecting approximately 500,000 people in the United States and these rare genetic diseases may be debilitating, chronic, and costly. Furthermore, as per the California Institute for Regenerative Medicine, severe combined immunodeficiency (SCID) is a rare genetic disorder, affecting one in 30,000 newborns.

Rising incidences of immune diseases in children and technological advancements in gene therapy are the key driving factors in the primary immunodeficiency therapeutics market.

Key Market Trends

Gene Therapy Segment is Expected to Hold a Major Market Share in the Primary Immunodeficiency Therapeutics Market

Most primary immunodeficiencies are genetic disorders. Gene therapy represents a life-saving alternative for those patients with severe forms of primary immunodeficiency diseases. Till now, gene therapy has been used to treat some of the primary immunodeficiencies diseases such as X-linked SCID, SCID secondary to adenosine deaminase (ADA) deficiency, CGD and WAS. According to the Immune Deficiency Foundation, common variable immune deficiency (CVID) is a relatively frequent form of primary immunodeficiency, affecting about 1 in 25,000 persons. Moreover, about 20% of patients have symptoms of the common variable immune deficiency (CVID) disease or are found to be immunodeficient in childhood because the immune system matures slow, and the diagnosis of CVID is generally not made until after the age of 4 years.

Gene therapy segment holds a significant market share in the primary immunodeficiency therapeutics market and is anticipated to show a similar trend over the forecast period due to the promising results of recent clinical trials, it is likely that gene therapies will become standard of care for a number of devastating diseases in the coming years.

Rising incidences of immune diseases in children and technological advancements in gene therapy are the key driving factors in the gene therapy segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global primary immunodeficiency therapeutics market due to rising prevalence of immunodeficiency diseases and technological advancements in genetic and stem cell therapy in this region. According to the Centers for Disease Control and Prevention, in the United States, babies born with severe combined immunodeficiency die before 1 year of age without medical treatment because immune system cannot fight against infection. Furthermore, increasing healthcare expenditure and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Primary Immunodeficiency Therapeutics Market is Consolidated competitive and consists of a few major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Baxter international Inc, Takeda Pharmaceutical Company Limited, CSL Ltd, Biotest AG, Octapharma AG, Kedrion Biopharma Inc, Bio Products Laboratory Limited, LFB group, Grifols S.A and Lupin Pharmaceuticals.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Baxter international Inc
  • Biotest AG
  • CSL Ltd
  • Grifols S.A
  • Kedrion Biopharma Inc
  • LFB group

1.1 Study Assumptions
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Immunodeficiency diseases
4.2.2 Technological Advancements in Genetic Therapy
4.3 Market Restraints
4.3.1 High Cost of the Therapies
4.3.2 Side Effects Associated with the Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Disease Type
5.1.1 Antibody Deficiency
5.1.2 Cellular Immunodeficiency
5.1.3 Innate Immune Disorders
5.1.4 Others
5.2 By Product Type
5.2.1 Immunoglobulin Replacement Therapy
5.2.2 Stem Cell/Bone Marrow Transplantation
5.2.3 Antibiotic Therapy
5.2.4 Gene Therapy
5.2.5 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Baxter international Inc
6.1.2 Takeda Pharmaceutical Company Limited
6.1.3 CSL Ltd
6.1.4 Octapharma AG
6.1.5 Biotest AG
6.1.6 Kedrion Biopharma Inc
6.1.7 Bio Products Laboratory Limited
6.1.8 LFB group
6.1.9 Grifols S.A
6.1.10 Lupin Pharmaceuticals
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Baxter international Inc
  • Takeda Pharmaceutical Company Limited
  • CSL Ltd
  • Octapharma AG
  • Biotest AG
  • Kedrion Biopharma Inc
  • Bio Products Laboratory Limited
  • LFB group
  • Grifols S.A
  • Lupin Pharmaceuticals
Note: Product cover images may vary from those shown